Fig 1: Effects of ERK pathway on Rap2B-induced MMP2 and MMP9 expression. An enzyme-linked immunosorbent assay showed MMP2 and MMP9 secretion in the supernatant of (A) U87 and (B) U251 glioma cells. Protein levels of MMP2 and MMP9 were determined by western blot analysis following treatment with Rap2B overexpression plasmids with or without SCH772984 in (C) U87 and (D) U251 cells. *P<0.05, **P<0.01 and ***P<0.001 vs. the control group. #P<0.05, ##P<0.01 and ###P<0.001 vs. the overexpressed Rap2B group. MMP, matrix metalloproteinase.
Fig 2: Effects of OMT on the releases of proinflammatory cytokines and MMP-2/-9 after IAV infection. A549 cells were seeded in 6-well plates for 24 h, then infected with or without IAV (ST169, H1N1), MOI = 0.001. In the ribavirin- and OMT-treated groups, the cells were further treated with ribavirin (25 μg/mL) and OMT (50 μg/mL), after 48 h, the supernatants and cells were collected and used in the ELISA assay. Data shown were mean ± SD of three independent experiments with three replicates. * p < 0.05, compared with the DMSO + virus (Vir) group.
Fig 3: Expression of MMPs, caspases, and cellular cyclin-related genes in LS174T cells of each group. (A) Expression of MMP2 in each group of LS174T cells. (B) Expression of MMP9 in each group of LS174T cells. (C) Expression of caspase-3 in each group of LS174T cells. (D) Expression of caspase-9 in each group of LS174T cells. (E) Expression of cyclin D1 in each group of LS174T cells. (F) Expression of CDK1 in each group of LS174T cells. Each experiment was repeated for 3 times independently. Data was presented as mean ± SD. P < .05 was set as a statistic difference. ∗P < 0.05 compared with normal control group, #P < .05 compared with cetuximab treatment group.
Fig 4: Concentration of invasion related factors in cultured medium. (A) Concentration of SDF-1α in cultured medium. (B) Concentration of E-cadherin in cultured medium. (C) Concentration of CXCL9 in cultured medium. (D) Concentration of CXCL10 in cultured medium. (E) Concentration of MMP-2 in cultured medium. (F) Concentration of MMP-9 in cultured medium. Each experiment was repeated for 3 times independently. Data was presented as mean ± SD. P < .05 was set as a statistic difference. ∗P < .05 compared with normal control group, #P < .05 compared with cetuximab treatment group.
Fig 5: Comparison of the serum levels of MMP-2, MMP-9, and vitamin D in seropositive/seronegative MS patients and healthy subjects. MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; MS, multiple sclerosis; HS, healthy subjects.
Supplier Page from Abcam for Human MMP2 ELISA Kit